Newly Founded Kenworthy Capital, an Impact Investment Fund Focused on

Autoimmune Diseases and Climate Change

Kenworthy Capital is a recently initiated impact investment fund that has vowed to donate a
percentage of income to fund research efforts on auto-immune disease like celiac disease.

Boston, MA, July 10, 2019 --(PR.com)-- Since 2016, early impact investment funds have become an
innovative investment management strategy to drive funds into research into climate change and the
health sector.

According to research, the private sector has invested up to $159.9 billion in pharmaceutical research
while a significant number of funds have been moved towards funding the $700 billion financial vacuum
identified by the OECD for successful climate change prevention.

Some of these investments come fromearly-impact investment funds designed to balance corporate and
public interests. Kenworthy Capital is one such recently founded early-stage impact investment fund This
investment fund will focus on investing in public and private companies with a focus in two-areas:

- Autoimmune Diseases - More than 80 diseases occur as a result of the immune system attacking the
body's own organs, tissues, and cells. Some of the more common autoimmune diseases include type 1
diabetes, celiac, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.

Although the causes of many autoimmune diseases remain unknown, a person's genes in combination
with infections and other environmental exposures are likely to play a significant role in disease
development. Treatments are available for many autoimmune diseases, but cures have yet to be
discovered.*

- Climate Change - Climate change represents one of the greatest threats of our time. There is a wide
variety of problem that needs addressing these include the social issues such as, alleviating the impact
from climate change-induced extreme weather events, reducing air pollution in cities, addressing ocean
plastics, transforming our energy system to clean energy or sustainable ways of food production, to
providing access to quality education and healthcare. Supporting efforts in the public and private sector to
address and solve the challenges of climate change is a core mission of Kenworthy Capital.

Among the various commitments that the company has made to the climate change and auto-immune
disease prevention, is the commitment that a percentage of founders' income from the fund will be
donated to non-profit based celiac research. Investors in the fund can also donate to research interests of
their particular interest but all returns will be at the discretion of the individual investors.

When asked for a comment, a spokesperson had this comment to offer:

“Auto-immune disease and climate change represent a major threat to the American society. The lack of
research and awareness of either of these issues puts us at risk of leaving the world in a worse position for

Page 1/3
PR.com Press Release Distribution Terms of Use
our children and the coming generations. For this reason, Kenworthy Capital was initiated to help
increase awareness and drive research efforts into tackling both of these concerns.”

About Kenworthy Capital

Kenworthy Capital is an early stage impact investment fund that caters to climate change and
auto-immune disease research. Contributing a part of incomes to either of these movements, Kenworthy
Capital balances out financial returns with awareness efforts for the environment and public health. The
fund was created by Inger and Randal Kenworthy to create investment returns while raising awareness of
impact investing and the need for research in diseases like celiac.

Contact Information:
Website: https://www.randalkenworthy.com/
Email: kenworthycapital@gmail.com

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
Kenworthy Capital
Randal Kenworthy
617-633-3714
Contact via Email
https://www.randalkenworthy.com/

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/789322

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use